



**Australian Government**

---

**Department of Health and Aged Care**

**Second Report on Key Performance Measures (KPM)**

for the

**Seventh Community Pharmacy Agreement (7CPA)**

November 2022

(Updated June 2023)

## Contents

<b>Index of Tables</b> .....	<b>2</b>
<b>Introduction</b> .....	<b>3</b>
<b>Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians</b> .....	<b>4</b>
a) Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).....	4
b) Transparency of charges (7CPA, Clause 4.3). .....	14
c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10). .....	15
d) Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4). .....	16
<b>Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies</b> .....	<b>17</b>
The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8). .....	17
<b>Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.</b> .....	<b>18</b>
a) Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14). .....	18
b) Accreditation of pharmacists for undertaking medication reviews.....	19
<b>Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines</b> .....	<b>20</b>
<b>Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas</b> .....	<b>22</b>

## Index of Tables

Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies) .....	5
Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies) .....	5
Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies).....	6
Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies) .....	6
Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies).....	6
Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies) .....	7
Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2021 .....	8
Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2021 .....	9
Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022 .....	10
Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies).....	11
Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies) .....	11
Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions .....	12
Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory.....	13
Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories.....	15
Table 1(d): Total expenditure on Electronic Prescription Fees .....	16
Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid .....	17
Table 3(b): Number of accredited registered pharmacists eligible to provide HMR and RMMR (as of 31 October 2022)* .....	19
Table 3(c): Number of accredited pharmacists actively providing HMRs and RMMRs .....	19
Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services .....	20
Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance .....	21
Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services .....	23

## Introduction

Key Performance Measures (KPM) for the Seventh Community Pharmacy Agreement (7CPA) were developed as an evaluation framework for operation of the 7CPA. The KPM aim to enable Government, the pharmacy sector and the community to assess impacts of the 7CPA, based on the available evidence, and whether objectives and health outcomes have been achieved effectively and efficiently under the 7CPA.

The KPM are a new undertaking under the 7CPA. No other evaluation mechanisms were developed under previous Community Pharmacy Agreements. As no specific funding has been made available under the 7CPA for monitoring and evaluation, the KPM have been confined to measures that stem from existing processes, available data and resources, with no additional costs to Government.

The KPM were developed in collaboration between the Department and key stakeholders including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Consumers Health Forum of Australia and the National Aboriginal Community Controlled Health Organisation.

KPM reports will be published on a biannual basis, subject to the availability of required data. The KPM will be reviewed in consultation with key stakeholders, named above.

Key objectives and outcomes to be monitored for the 7CPA are to:

1. Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians;
2. Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies;
3. Support professional initiatives for pharmacists to better fulfil their current scope of practice;
4. Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines; and
5. Support access to medicines and pharmacy services for Australians in regional, rural, and remote areas.

This is the second KPM report, presenting information relevant to the following three six-month reporting periods under the 7CPA:

**1 January – 30 June 2021; 1 July – 31 December 2021; and 1 January – 30 June 2022.**

The information in this document should be read in conjunction with the [KPM for the 7CPA](#) and [KPM for 7CPA – Key Policy Principles](#), which are each available on the Department of Health and Aged Care's [website](#). The first KPM report can also be accessed at:

[www.pbs.gov.au/info/general/key-performance-measures-for-the-seventh-community-pharmacy](http://www.pbs.gov.au/info/general/key-performance-measures-for-the-seventh-community-pharmacy).

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

a) ***Provision of pharmaceutical benefits in accordance with applicable laws, regulations, professional standards, codes and other requirements (7CPA, Clause 7).***

The following tables present information on:

- Total prescriptions and expenditure for s90 pharmacies<sup>1</sup>, for PBS and Repatriation Pharmaceutical Benefits Scheme (RPBS) items by patient category and state / territory – *Tables 1(a)-1, 1(a)-2, 1(a)-3, 1(a)-4, 1(a)-5, 1(a)-7, 1(a)-8 and 1(a)-9*
- Patient contribution and Government cost for PBS items dispensed by s90 pharmacies – *Table 1(a)-6*
- Over and under co-payment PBS prescriptions for items dispensed by s90 pharmacies – *Table 1(a)-2*
- Discounted and non-discounted PBS/RPBS items dispensed by s90 pharmacies – *Tables 1(a)-10 and 1(a)-11*
- PBS remuneration for s90 pharmacies and wholesalers – *Tables 1(a)-12*
- PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services – *Tables 1(a)-13*

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia. Data were extracted on 24 October 2022. Please note that the figures provided are subject to change due to late claims and adjustments by pharmacies.

---

<sup>1</sup> **“s90 Pharmacies”** are those pharmacies operated by a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from particular pharmacy premises. Other suppliers include approved doctors (usually practising in isolated areas) and approved hospitals.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-1: Total PBS Expenditure by Patient Category (s90 Pharmacies)**

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	PBS Expenditure	Percentage	PBS Expenditure	Percentage	PBS Expenditure	Percentage
Section 85 - Concessional	\$3,020,333,415	61.3%	\$3,587,795,173	62.3%	\$3,166,222,454	59.2%
Section 85 - General	\$1,101,059,315	22.4%	\$1,319,579,587	22.9%	\$1,349,898,412	25.2%
Doctor's Bag	\$7,457,164	0.2%	\$6,792,987	0.1%	\$7,434,412	0.1%
Section 100	\$796,953,411	16.2%	\$843,605,549	14.7%	\$823,316,538	15.4%
<b>Total</b>	<b>\$4,925,803,305</b>	<b>100.0%</b>	<b>\$5,757,773,296</b>	<b>100.0%</b>	<b>\$5,346,871,816</b>	<b>100.0%</b>

Note: Excludes expenditure for RPBS items.

**Table 1(a)-2: PBS Prescription volumes by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag and under co-payment prescriptions

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	PBS prescriptions	Percentage	PBS prescriptions	Percentage	PBS prescriptions	Percentage
Concessional Non-Safety Net	85,712,721	86.3%	56,277,529	50.5%	85,468,956	85.4%
Concessional Safety Net	5,799,223	5.8%	44,391,270	39.9%	5,811,228	5.8%
<b>Total Concessional</b>	<b>91,511,944</b>	<b>92.2%</b>	<b>100,668,799</b>	<b>90.4%</b>	<b>91,280,184</b>	<b>91.2%</b>
General Non-Safety Net	7,489,760	7.5%	7,785,899	7.0%	8,496,950	8.5%
General Safety Net	114,690	0.1%	2,730,991	2.5%	109,871	0.1%
<b>Total General</b>	<b>7,604,450</b>	<b>7.7%</b>	<b>10,516,890</b>	<b>9.4%</b>	<b>8,606,821</b>	<b>8.6%</b>
Doctors Bag	183,911	0.2%	165,860	0.1%	189,580	0.2%
<b>Total (Over Co-payment)</b>	<b>99,300,305</b>	<b>100.0%</b>	<b>111,351,549</b>	<b>100.0%</b>	<b>100,076,585</b>	<b>100.0%</b>
Under Co-payment scripts	47,277,503		48,466,911		50,797,169	
<b>Total (Over and Under Co-payment)</b>	<b>146,577,808</b>		<b>159,818,460</b>		<b>150,873,754</b>	

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-3: PBS Government Cost by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag and excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Concessional Non-Safety Net	\$3,208,008,735	65.1%	\$2,322,869,670	40.3%	\$3,349,075,731	62.6%
Concessional Safety Net	\$216,817,335	4.4%	\$1,693,323,829	29.4%	\$230,839,429	4.3%
<b>Total Concessional</b>	<b>\$3,424,826,070</b>	<b>69.5%</b>	<b>\$4,016,193,499</b>	<b>69.8%</b>	<b>\$3,579,915,160</b>	<b>67.0%</b>
General Non-Safety Net	\$1,488,211,524	30.2%	\$1,599,951,483	27.8%	\$1,753,836,385	32.8%
General Safety Net	\$5,308,546	0.1%	\$134,835,327	2.3%	\$5,685,860	0.1%
<b>Total General</b>	<b>\$1,493,520,070</b>	<b>30.3%</b>	<b>\$1,734,786,810</b>	<b>30.1%</b>	<b>\$1,759,522,245</b>	<b>32.9%</b>
Doctors Bag	\$7,457,164	0.2%	\$6,792,987	0.1%	\$7,434,412	0.1%
<b>Total (Over Co-payment)</b>	<b>\$4,925,803,305</b>	<b>100.0%</b>	<b>\$5,757,773,296</b>	<b>100.0%</b>	<b>\$5,346,871,816</b>	<b>100.0%</b>

**Table 1(a)-4: RPBS and PBS Prescription volumes for DVA patients (s90 Pharmacies)**

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage	Subsidised prescriptions	Percentage
Repatriation Non-Safety Net	3,225,236	90.8%	1,690,524	45.3%	3,073,958	90.9%
Repatriation Safety Net	328,177	9.2%	2,045,201	54.7%	309,208	9.1%
<b>Total Repatriation</b>	<b>3,553,413</b>	<b>100.0%</b>	<b>3,735,725</b>	<b>100.0%</b>	<b>3,383,166</b>	<b>100.0%</b>

**Table 1(a)-5: RPBS and PBS Government Cost for DVA patients (s90 Pharmacies)**

PBS Section 85 and Section 100 and RPBS items for DVA patients, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Government Cost	Percentage	Government Cost	Percentage	Government Cost	Percentage
Repatriation Non-Safety Net	\$117,100,472.07	90.7%	\$74,270,792.35	49.9%	\$122,278,592	91.0%
Repatriation Safety Net	\$12,003,027.81	9.3%	\$74,575,519.13	50.1%	\$12,153,585	9.0%
<b>Total Repatriation</b>	<b>\$129,103,500</b>	<b>100.0%</b>	<b>\$148,846,311</b>	<b>100.0%</b>	<b>\$134,432,177</b>	<b>100.0%</b>

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-6: Patient Contribution and Government Cost by Patient Category (s90 Pharmacies)**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Patient Category	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost	Patient Contribution*	Government Cost
Concessional Non-Safety Net	\$547,002,944	\$3,208,008,735	\$356,789,189	\$2,322,869,670	\$559,827,415	\$3,349,075,731
Concessional Safety Net	\$0	\$216,817,335	\$0	\$1,693,323,829	\$0	\$230,839,429
<b>Total Concessional</b>	<b>\$547,002,944</b>	<b>\$3,424,826,070</b>	<b>\$356,789,189</b>	<b>\$4,016,193,499</b>	<b>\$559,827,415</b>	<b>\$3,579,915,160</b>
General Non-Safety Net	\$276,710,349	\$1,488,211,524	\$285,688,978	\$1,599,951,483	\$319,261,425	\$1,753,836,385
General Safety Net	\$721,611	\$5,308,546	\$17,387,053	\$134,835,327	\$715,408	\$5,685,860
<b>Total General</b>	<b>\$277,431,960</b>	<b>\$1,493,520,070</b>	<b>\$303,076,031</b>	<b>\$1,734,786,810</b>	<b>\$319,976,832</b>	<b>\$1,759,522,245</b>
<b>Total (excl. Drs Bag)</b>	<b>\$824,434,904</b>	<b>\$4,918,346,140</b>	<b>\$659,865,220</b>	<b>\$5,750,980,309</b>	<b>\$879,804,247</b>	<b>\$5,339,437,405</b>
Doctors Bag	\$0	\$7,457,164	\$0	\$6,792,987	\$0	\$7,434,412
<b>Total (Incl. Drs Bag)</b>	<b>\$824,434,904</b>	<b>\$4,925,803,305</b>	<b>\$659,865,220</b>	<b>\$5,757,773,296</b>	<b>\$879,804,247</b>	<b>\$5,346,871,816</b>

\* The patient contribution does not include the effect of the \$1 PBS patient co-payment discount.



Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-7: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2021**

*Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions*

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	27,840,435	21,118,305	17,906,932	7,244,386	7,907,166	2,485,630	312,241	897,626	85,712,721
<b>Concessional Safety Net</b>	2,089,079	1,338,031	1,210,502	462,651	455,744	174,124	8,306	60,786	5,799,223
<b>General Non-Safety Net</b>	2,514,649	1,730,476	1,539,307	473,157	826,000	165,665	71,278	169,228	7,489,760
<b>General Safety Net</b>	41,347	29,639	19,402	6,253	12,108	1,921	346	3,674	114,690
<b>Total</b>	<b>32,485,510</b>	<b>24,216,451</b>	<b>20,676,143</b>	<b>8,186,447</b>	<b>9,201,018</b>	<b>2,827,340</b>	<b>392,171</b>	<b>1,131,314</b>	<b>99,116,394</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,157,168,782	\$732,802,938	\$632,399,217	\$250,197,571	\$307,077,886	\$84,077,781	\$9,914,810	\$34,369,750	\$3,208,008,735
<b>Concessional Safety Net</b>	\$77,123,800	\$50,352,312	\$44,474,121	\$17,071,220	\$18,137,837	\$6,874,923	\$278,068	\$2,505,054	\$216,817,335
<b>General Non-Safety Net</b>	\$549,532,401	\$357,410,298	\$258,277,389	\$89,640,077	\$168,717,984	\$27,946,124	\$6,939,553	\$29,747,697	\$1,488,211,524
<b>General Safety Net</b>	\$1,811,740	\$1,470,162	\$900,787	\$237,988	\$568,812	\$125,269	\$9,410	\$184,378	\$5,308,546
<b>Total</b>	<b>\$1,785,636,722</b>	<b>\$1,142,035,710</b>	<b>\$936,051,514</b>	<b>\$357,146,856</b>	<b>\$494,502,521</b>	<b>\$119,024,096</b>	<b>\$17,141,843</b>	<b>\$66,806,879</b>	<b>\$4,918,346,140</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,333,455,046	\$870,750,389	\$745,297,602	\$296,728,469	\$357,333,738	\$99,800,862	\$11,479,598	\$40,165,976	\$3,755,011,680
<b>Concessional Safety Net</b>	\$77,123,800	\$50,352,312	\$44,474,121	\$17,071,220	\$18,137,837	\$6,874,923	\$278,068	\$2,505,054	\$216,817,335
<b>General Non-Safety Net</b>	\$639,936,155	\$426,151,965	\$312,867,146	\$107,478,763	\$199,435,766	\$33,847,220	\$8,875,354	\$36,329,505	\$1,764,921,873
<b>General Safety Net</b>	\$2,072,030	\$1,662,889	\$1,021,409	\$275,033	\$642,686	\$136,773	\$11,423	\$207,914	\$6,030,157
<b>Total</b>	<b>\$2,052,587,031</b>	<b>\$1,348,917,554</b>	<b>\$1,103,660,278</b>	<b>\$421,553,486</b>	<b>\$575,550,028</b>	<b>\$140,659,777</b>	<b>\$20,644,443</b>	<b>\$79,208,448</b>	<b>\$5,742,781,045</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (Section 85 and Section 100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-8: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 July – 31 December 2021**

*Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions*

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	17,882,347	13,937,920	11,899,062	4,733,609	5,396,426	1,586,256	255,478	586,431	56,277,529
<b>Concessional Safety Net</b>	14,856,405	10,803,902	9,215,769	3,715,194	3,933,118	1,318,292	90,600	457,990	44,391,270
<b>General Non-Safety Net</b>	2,563,096	1,818,272	1,624,961	483,139	874,586	174,515	77,788	169,542	7,785,899
<b>General Safety Net</b>	941,342	653,429	497,934	180,340	313,799	55,977	9,138	79,032	2,730,991
<b>Total</b>	<b>36,243,190</b>	<b>27,213,523</b>	<b>23,237,726</b>	<b>9,112,282</b>	<b>10,517,929</b>	<b>3,135,040</b>	<b>433,004</b>	<b>1,292,995</b>	<b>111,185,689</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$855,022,099	\$526,396,466	\$451,822,545	\$174,416,933	\$226,425,153	\$56,978,707	\$8,407,094	\$23,400,673	\$2,322,869,670
<b>Concessional Safety Net</b>	\$569,367,413	\$410,131,799	\$344,883,177	\$139,939,639	\$156,374,259	\$50,826,545	\$3,082,309	\$18,718,689	\$1,693,323,829
<b>General Non-Safety Net</b>	\$582,245,386	\$391,875,949	\$278,618,785	\$96,756,044	\$180,829,114	\$30,543,635	\$8,189,718	\$30,892,851	\$1,599,951,483
<b>General Safety Net</b>	\$45,974,717	\$33,540,996	\$23,693,454	\$8,496,971	\$15,926,077	\$2,828,861	\$352,993	\$4,021,258	\$134,835,327
<b>Total</b>	<b>\$2,052,609,615</b>	<b>\$1,361,945,211</b>	<b>\$1,099,017,961</b>	<b>\$419,609,587</b>	<b>\$579,554,602</b>	<b>\$141,177,748</b>	<b>\$20,032,114</b>	<b>\$77,033,471</b>	<b>\$5,750,980,309</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$967,462,788	\$617,249,215	\$525,993,029	\$204,707,059	\$260,394,574	\$66,974,539	\$9,700,535	\$27,177,120	\$2,679,658,859
<b>Concessional Safety Net</b>	\$569,367,413	\$410,131,799	\$344,883,177	\$139,939,639	\$156,374,259	\$50,826,545	\$3,082,309	\$18,718,689	\$1,693,323,829
<b>General Non-Safety Net</b>	\$673,721,430	\$464,141,490	\$335,233,912	\$115,005,093	\$213,151,913	\$36,650,525	\$10,271,684	\$37,464,412	\$1,885,640,461
<b>General Safety Net</b>	\$51,934,847	\$37,804,847	\$26,803,770	\$9,652,803	\$17,920,947	\$3,173,216	\$398,579	\$4,533,372	\$152,222,380
<b>Total</b>	<b>\$2,262,486,478</b>	<b>\$1,529,327,351</b>	<b>\$1,232,913,888</b>	<b>\$469,304,594</b>	<b>\$647,841,693</b>	<b>\$157,624,824</b>	<b>\$23,453,108</b>	<b>\$87,893,594</b>	<b>\$6,410,845,529</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-9: PBS Prescriptions by Pharmacy State/Territory and Patient Category (s90 Pharmacies), 1 January – 30 June 2022**

*Section 85 and Section 100, excluding Drs Bag and excluding under co-payment prescriptions*

<b>PBS Prescriptions</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	27,646,960	21,153,765	17,831,256	7,204,947	7,929,709	2,497,069	307,620	897,630	85,468,956
<b>Concessional Safety Net</b>	2,027,964	1,383,481	1,214,205	464,795	473,066	175,704	8,494	63,519	5,811,228
<b>General Non-Safety Net</b>	2,815,800	1,972,755	1,770,277	527,445	952,411	190,529	79,876	187,857	8,496,950
<b>General Safety Net</b>	37,305	29,936	17,936	6,163	12,267	2,087	290	3,887	109,871
<b>Total</b>	<b>32,528,029</b>	<b>24,539,937</b>	<b>20,833,674</b>	<b>8,203,350</b>	<b>9,367,453</b>	<b>2,865,389</b>	<b>396,280</b>	<b>1,152,893</b>	<b>99,887,005</b>
<b>Government Cost</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,194,373,832	\$775,214,401	\$655,211,556	\$262,201,009	\$327,563,083	\$88,509,999	\$10,013,491	\$35,988,360	\$3,349,075,731
<b>Concessional Safety Net</b>	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
<b>General Non-Safety Net</b>	\$633,055,471	\$427,862,141	\$306,999,143	\$107,975,641	\$199,393,377	\$34,439,187	\$8,593,886	\$35,517,539	\$1,753,836,385
<b>General Safety Net</b>	\$1,885,601	\$1,663,153	\$879,478	\$276,014	\$676,624	\$123,137	\$8,974	\$172,877	\$5,685,860
<b>Total</b>	<b>\$1,908,932,349</b>	<b>\$1,260,235,086</b>	<b>\$1,009,988,437</b>	<b>\$388,848,919</b>	<b>\$547,744,603</b>	<b>\$130,402,667</b>	<b>\$18,904,754</b>	<b>\$74,380,592</b>	<b>\$5,339,437,405</b>
<b>Total Cost*</b>									
<b>Categories</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
<b>Concessional Non-Safety Net</b>	\$1,374,013,730	\$917,339,909	\$770,264,510	\$309,818,159	\$379,276,348	\$104,654,845	\$11,589,534	\$41,946,112	\$3,908,903,146
<b>Concessional Safety Net</b>	\$79,617,445	\$55,495,391	\$46,898,260	\$18,396,254	\$20,111,519	\$7,330,343	\$288,402	\$2,701,816	\$230,839,429
<b>General Non-Safety Net</b>	\$735,855,407	\$508,393,270	\$370,035,337	\$128,410,173	\$235,473,742	\$41,209,843	\$10,744,544	\$42,975,493	\$2,073,097,810
<b>General Safety Net</b>	\$2,126,689	\$1,863,216	\$993,705	\$316,128	\$755,953	\$136,023	\$10,715	\$198,839	\$6,401,267
<b>Total</b>	<b>\$2,191,613,270</b>	<b>\$1,483,091,785</b>	<b>\$1,188,191,810</b>	<b>\$456,940,714</b>	<b>\$635,617,562</b>	<b>\$153,331,054</b>	<b>\$22,633,195</b>	<b>\$87,822,261</b>	<b>\$6,219,241,652</b>

\* Total Cost includes cost to the patient and cost to the Government for PBS Subsidised Prescriptions (S85 and S100 prescriptions).

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-10: Discounted and Non-Discounted PBS/RPBS Prescriptions (s90 Pharmacies)**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Prescription Type	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 January – 30 June 2021	Discounted	26,236,002	29%	2,441,424	32%	614,149	17%	29,291,575	29%
	Non-discounted	65,275,942	71%	5,163,026	68%	2,939,264	83%	73,378,232	71%
	<b>Grand Total</b>	<b>91,511,944</b>	<b>100%</b>	<b>7,604,450</b>	<b>100%</b>	<b>3,553,413</b>	<b>100%</b>	<b>102,669,807</b>	<b>100%</b>
1 July – 31 December 2021	Discounted	21,348,221	21%	3,102,456	29%	470,131	13%	24,920,808	22%
	Non-discounted	79,320,578	79%	7,414,434	71%	3,265,594	87%	90,000,606	78%
	<b>Grand Total</b>	<b>100,668,799</b>	<b>100%</b>	<b>10,516,890</b>	<b>100%</b>	<b>3,735,725</b>	<b>100%</b>	<b>114,921,414</b>	<b>100%</b>
1 January – 30 June 2022	Discounted	25,437,223	28%	2,704,488	31%	597,861	18%	28,739,572	28%
	Non-discounted	65,842,961	72%	5,902,333	69%	2,785,305	82%	74,530,599	72%
	<b>Grand Total</b>	<b>91,280,184</b>	<b>100%</b>	<b>8,606,821</b>	<b>100%</b>	<b>3,383,166</b>	<b>100%</b>	<b>103,270,171</b>	<b>100%</b>

**Table 1(a)-11: Discount Range for PBS/RPBS prescriptions (s90 Pharmacies)**

Section 85 and Section 100, excluding Drs Bag and under co-payment prescriptions

Report Period	Discount Range	Concessional		General		RPBS		Total	
		Prescriptions	%	Prescriptions	%	Prescriptions	%	Prescriptions	%
1 January – 30 June 2021	\$1.00	25,593,905	97.6%	2,406,140	98.6%	595,736	97.0%	28,595,781	97.6%
	0.50 - < \$1.00	399,226	1.5%	20,034	0.8%	10,257	1.7%	429,517	1.5%
	< 50c	152,168	0.6%	9,344	0.4%	5,053	0.8%	166,565	0.6%
	Other	90,703	0.3%	5,906	0.2%	3,103	0.5%	99,712	0.3%
	<b>Grand Total</b>	<b>26,236,002</b>	<b>100.0%</b>	<b>2,441,424</b>	<b>100.0%</b>	<b>614,149</b>	<b>100.0%</b>	<b>29,291,575</b>	<b>100.0%</b>
1 July – 31 December 2021	\$1.00	20,875,358	97.8%	3,051,355	98.4%	457,560	97.3%	24,384,273	97.8%
	0.50 - < \$1.00	302,196	1.4%	27,030	0.9%	7,557	1.6%	336,783	1.4%
	< 50c	104,055	0.5%	10,839	0.3%	3,001	0.6%	117,895	0.5%
	Other	66,612	0.3%	13,232	0.4%	2,013	0.4%	81,857	0.3%
	<b>Grand Total</b>	<b>21,348,221</b>	<b>100.0%</b>	<b>3,102,456</b>	<b>100.0%</b>	<b>470,131</b>	<b>100.0%</b>	<b>24,920,808</b>	<b>100.0%</b>
1 January – 30 June 2022	\$1.00	24,811,755	97.5%	2,666,561	98.6%	580,641	97.1%	28,058,957	97.6%
	0.50 - < \$1.00	378,805	1.5%	23,565	0.9%	9,574	1.6%	411,944	1.4%
	< 50c	108,113	0.4%	4,394	0.2%	3,635	0.6%	116,142	0.4%
	Other	138,550	0.5%	9,968	0.4%	4,011	0.7%	152,529	0.5%
	<b>Grand Total</b>	<b>25,437,223</b>	<b>100.0%</b>	<b>2,704,488</b>	<b>100.0%</b>	<b>597,861</b>	<b>100.0%</b>	<b>28,739,572</b>	<b>100.0%</b>

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-12: Remuneration to s90 Pharmacies and wholesalers for PBS/RPBS Prescriptions**

Section 85 and Section 100, including Drs Bag, excluding under co-payment prescriptions

Pharmacy remuneration recognises the cost to pharmacist for the purchase of medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

Expenses for PBS and RPBS Prescriptions	1 January – 30 June 2021	1 July – 31 December 2021	1 January – 30 June 2022
<b>Medicines Price</b>			
Ex-Manufacturer Price	\$3,704,844,309	\$4,236,365,629	\$4,205,920,812
Wholesale Mark-Up	\$206,665,455	\$231,742,582	\$225,682,221
<b>Total Price to Pharmacist</b>	<b>\$3,911,509,765</b>	<b>\$4,468,108,211</b>	<b>\$4,431,603,033</b>
<b>Pharmacy Costs</b>			
Administration, Handling and Infrastructure (AHI) fee	\$537,658,267	\$603,588,682	\$555,546,889
Dispensing Fee	\$790,456,331	\$889,213,495	\$797,892,501
Dangerous Drug Fee	\$19,812,029	\$21,398,915	\$19,834,830
Wastage Fee	\$2,614,807	\$3,259,737	\$3,080,697
Container Fee	\$756,161	\$619,663	\$516,403
<b>Total Pharmacy Remuneration</b>	<b>\$1,351,297,595</b>	<b>\$1,518,080,492</b>	<b>\$1,376,871,320</b>
<b>Total Cost</b>	<b>\$5,262,807,359</b>	<b>\$5,986,188,703</b>	<b>\$5,808,474,352</b>

Data is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions.

Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

**Table 1(a)-13: Volume and Expenditure of PBS items supplied in bulk and individually for clients of Remote Area Aboriginal Health Services (RAAHS) by state/territory**

Report Period	RAHHS Supply	NSW/TAS*	NT	QLD	SA	WA	Australia
<b>1 January – 30 June 2021</b>	Total Items**	2,836	411,736	143,077	33,883	205,676	<b>797,208</b>
	Total Items Cost	\$61,350	\$10,694,145	\$4,035,255	\$918,975	\$5,093,228	<b>\$20,802,953</b>
	Individual Items***	311	239,833	73,942	15,352	130,601	<b>460,039</b>
	Individual Items cost	\$1,527	\$1,176,902	\$363,075	\$74,396	\$641,251	<b>\$2,257,151</b>
<b>1 July – 31 December 2021</b>	Total Items**	4,494	400,269	123,959	32,566	225,864	<b>787,152</b>
	Total Items Cost	\$103,503	\$10,369,125	\$3,501,937	\$848,248	\$5,776,082	<b>\$20,598,895</b>
	Individual Items***	549	265,514	63,811	17,351	140,509	<b>487,734</b>
	Individual Items cost	\$2,699	\$1,313,623	\$315,657	\$85,872	\$695,988	<b>\$2,413,839</b>
<b>1 January – 30 June 2022</b>	Total Items**	5374	497,489	176,556	32,414	238,777	<b>950,610</b>
	Total Items Cost	\$132,617	\$12,942,427	\$5,197,948	\$888,138	\$5,872,765	<b>\$25,033,896</b>
	Individual Items***	1,645	338,080	108,388	14,298	141,558	<b>603,969</b>
	Individual Items cost	\$8,157	\$1,676,877	\$537,595	\$70,918	\$702,110	<b>\$2,995,656</b>

Note: there are no RAAHS data for VIC and ACT.

\* Data for NSW and Tasmania have been aggregated to prevent identification due to low number of individual data points available.

\*\* Total Items includes items supplied in bulk and individually.

\*\*\* Items supplied individually are taken from the no. of instances of the Patient Specific Medicine Supply Fee (PSMSF) paid for each PBS medicine ordered on a RAAHS prescription, and labelled for an individual patient, for supply through an approved RAAHS.

The PSMSF is paid in addition to the handling fee paid to eligible pharmacies for the supply of bulk PBS medicines to an approved RAAHS.

The PSMSF figures are a subset of the RAAHS figures.

From 1 July 2020 to 30 June 2021 the PSMSF was \$4.91 and from 1 July 2021 to 30 June 2022 the PSMSF was \$4.96.

The PSMSF data has been manually extracted from Services Australia Remote Area Aboriginal Health Services Access data base and is not sourced from official channels.

This data relates to the date claims are processed and may differ from other data provided by Services Australia, including PBS Expenditure data.

PSMSF values maybe affected by rounding

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### b) **Transparency of charges (7CPA, Clause 4.3).**

Clause 4.3 of the Seventh Community Pharmacy Agreement (7CPA) committed the Pharmacy Guild of Australia (Guild) to ensuring that Approved Pharmacists<sup>2</sup> “make consumers aware, prior to dispensing a Pharmaceutical Benefit, of any Safety Net Recording Fee and Additional Patient Charge to be charged, the fact that the Additional Patient Charge is not Commonwealth initiated, and the total cost to the consumer of that Pharmaceutical Benefit.” During the First Financial Year of the 7CPA, the Guild was required to work with the Department to develop arrangements and processes to support this commitment.

Following discussion at the first meeting of the 7CPA Pharmacy Stakeholder Consultation Committee (PSCC) in October 2020, the Guild worked with the Department to develop arrangements and processes for Approved Pharmacists to make the required disclosures and to notify consumers, prior to dispensing, of the price of the Pharmaceutical Benefit.

The draft communication resources and materials developed by the Guild, consisting of an in-pharmacy poster and supporting Frequently Asked Questions (FAQ), were subsequently discussed at the second PSCC meeting in April 2021, with further consultations between the Department, the Pharmaceutical Society of Australia (PSA), Consumers Health Forum of Australia (CHF) and the National Aboriginal Community Controlled Health Organisation (NACCHO), leading to consumer focus testing hosted by CHF and the Guild.

Following endorsement of the Guild’s communication resources by PSCC in July 2021, the resources were published on the Guild’s [FindaPharmacy](#) website on 1 January 2022, to coincide with annual PBS patient co-payment changes.

The Guild will continue to provide regular updates on progress and uptake of its PBS medicines pricing resources at biannual meetings of the PSCC. Communiqués arising from each meeting of the PSCC are published on the [Department’s website](#).

---

<sup>2</sup> An “**approved pharmacist**” means a pharmacist approved under section 90 of the *National Health Act 1953* to dispense pharmaceutical benefits from particular pharmacy premises.

## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### c) Closing the Gap (CTG) PBS Co-Payment Program (7CPA, Clause 10).

The CTG PBS Co-payment program was established in July 2010 to improve access to affordable PBS medicines for Aboriginal and Torres Strait Islander people living with, or at risk of, chronic disease, and who in their doctor's opinion would experience setbacks in the prevention or ongoing management of chronic disease if they did not take the prescribed medicine and would be unlikely to adhere to their medicines regimen without assistance through the program.

When obtaining PBS General Schedule medicines at their local pharmacy, eligible general patients who would normally pay the full PBS co-payment pay the concessional rate and those eligible patients who would normally pay the concessional rate receive their PBS medicines without being required to pay a PBS co-payment.

The following table presents information on the total number of PBS items and expenditure for the CTG PBS Co-Payment Program across states and territories. This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

**Table 1(c): Total number of PBS items and expenditure for CTG PBS Co-Payment Program across states and territories**

Pharmacy State/Territory	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount	No. of PBS items	CTG Benefit Amount
<b>ACT</b>	32,750	\$321,403	36,572	\$306,032	38,044	\$388,038
<b>NSW</b>	1,477,735	\$12,287,239	1,678,691	\$10,933,459	1,670,425	\$14,591,200
<b>NT</b>	106,058	\$952,546	117,227	\$912,899	112,822	\$1,066,306
<b>QLD</b>	1,104,297	\$9,224,925	1,349,344	\$9,096,850	1,310,573	\$11,514,246
<b>SA</b>	244,270	\$1,936,499	269,215	\$1,692,801	266,958	\$2,226,997
<b>TAS</b>	143,941	\$1,133,784	174,459	\$1,011,864	174,733	\$1,454,866
<b>VIC</b>	287,334	\$2,381,214	331,688	\$2,154,362	333,794	\$2,903,246
<b>WA</b>	385,846	\$3,272,666	460,586	\$3,196,985	442,403	\$3,927,907
<b>Total</b>	<b>3,782,231</b>	<b>\$31,510,276</b>	<b>4,417,782</b>	<b>\$29,305,252</b>	<b>4,349,752</b>	<b>\$38,072,805</b>



## Objective 1: Demonstrate transparency and accountability while supplying Pharmaceutical Benefits Scheme (PBS) medicines for all Australians

### d) *Support the uptake of electronic prescription arrangements (7CPA, Clause 9.4).*

Electronic prescribing provides an option for prescribers and their patients to use an electronic prescription as an alternative to a paper prescription. Electronic prescriptions are part of the broader digital health and medicines safety framework and are part of an Australian Government budget measure to make the PBS more efficient. Electronic prescribing aims to provide convenience and choice to patients while improving PBS efficiency, compliance and medicines safety. Electronic prescribing does not fundamentally change existing prescribing and dispensing processes: patients can still choose which pharmacy they attend to fill their prescription; and paper prescriptions are still available.

An Electronic Prescription Fee (EPF) is paid to pharmacies for the dispensing of electronic prescriptions.

Under the 7CPA (clause 9.4), the Commonwealth continues to support the uptake of electronic prescriptions by Approved Pharmacists. Following the first financial year of the 7CPA, the EPF will transition to a direct funding arrangement with Exchange Infrastructure Providers rather than Approved Pharmacists.

This report has been produced using PBS online claims data maintained by the Department of Health and Aged Care and sourced from Services Australia.

**Table 1(d): Total expenditure on Electronic Prescription Fees**

Cost (PBS and RPBS Prescriptions)	1 January – 30 June 2021	1 July – 31 December 2021	1 January – 30 June 2022
Electronic Prescription Fee	\$7,339,243	\$9,626,492	\$9,705,446

## Objective 2: Continue to supply National Diabetes Services Scheme (NDSS) products through community pharmacies

### *The National Diabetes Services Scheme (NDSS) (7CPA, Clause 6 and 8).*

Approved community pharmacy Access Points receive a payment of \$1 plus GST for each NDSS product pack supplied to registrants.

Community Service Obligation Distributors (CSODs) receive a payment of \$1 plus GST for each NDSS product pack delivered to NDSS Access Points.

**Table 2: NDSS Registrants, Community pharmacy Access Points and handling fees paid**

Category	1 January – 30 June 2021	1 July – 31 December 2021	1 January – 30 June 2022
<b>Total No. of NDSS registrants</b>	1,389,475	1,426,245	1,454,169
<b>Registrants registered on the NDSS Gestational Diabetes Mellitus Reminder Register</b>	168,177	169,543	175,476
<b>Total No. of approved community pharmacy NDSS Access Points</b>	5,638	5,650	5,904
<b>Total Access Point Fees Paid</b>	\$3,207,656	\$3,370,193	\$3,142,066

### Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

a) ***Pharmaceutical Society of Australia (PSA) Professional Practice Standards (PPS), Practice Guidelines, and Code of Ethics (CoE) (7CPA, Clause 14).***

Clause 14.2 of the Seventh Community Pharmacy Agreement (7CPA) commits the Pharmaceutical Society of Australia (PSA) and the Department of Health and Aged Care, to working together in relation to the further development of the PSA Code of Ethics that underpins pharmacist practice in Australia.

Following review of the PSA's proposed update of the PSA Code of Ethics, presented to the Department in late 2021, the Department has chosen not to pursue this update at this time.

Clause 14.6 of the 7CPA commits the PSA to continue to maintain the Professional Practice Standards (PPS) and relevant clinical guidelines with the aim of providing pharmacists with practice information to support the safe and quality use of medicines.

As part of this work, the Department entered into a contract with PSA in October 2021, to redevelop the Guidelines for Medication Management for Aboriginal and Torres Strait Islander people. This work was successfully completed during the first half of 2022 and the redeveloped "[Guidelines for Pharmacists supporting Aboriginal and Torres Strait Islander Peoples with Medicines Management](#)" were published in July 2022.

Similarly, in April 2022, the Department entered into a contract with PSA to update the PPS. This update is expected to be completed by 30 June 2023.

As part of this work, the PSA will also update some clinical guidelines, including those associated with Continuous Dispensing arrangements.

## Objective 3: Support professional initiatives for pharmacists to better fulfil their current scope of practice.

### b) Accreditation of pharmacists for undertaking medication reviews

Home Medicines Reviews (HMR) and Residential Medication Management Reviews (RMMR) are medication management services initiated and supported by the Australian Government, aimed at supporting the quality use of medicines and assisting in minimising adverse medicine events by helping people understand and manage their medicines. Medication reviews are initiated by a medical practitioner and conducted by an accredited pharmacist. The HMR involves an accredited pharmacist making a home visit to a patient’s home to provide a medication review service, while the RMMR service is provided to an eligible patient residing in an eligible Residential Care Facility. In both HMR and RMMR, after the initial interview, the accredited pharmacist provides an HMR or RMMR report respectively to the initiating medical practitioner for consideration of issues raised.

From 21 April 2020, if clinically indicated, up to two follow-up services may be conducted to resolve medication-related problems identified at the initial interview.

**Table 3(b)-1: Number of accredited registered pharmacists eligible to provide HMR and RMMR (as of 31 October 2022)\***

Category	Number	Percentage of Registered Pharmacists
Accredited registered pharmacists	2141	6.1%
<b>Total registered pharmacists** (as of 30 June 2022)</b>	<b>35,368</b>	

\* Information sourced from data published by [The Society of Hospital Pharmacy of Australia \(SHPA\)](#), [Australian Association of Consultant Pharmacy \(AACP\)](#) and [Pharmacy Board of Australia \(PBA\)](#).

\*\* Includes 642 pharmacists on the short-term pandemic response sub-register (this register closed on 22 September 2022).

Note: An accredited pharmacist can provide both HMR and RMMR services.

**Table 3(b)-2: Number of accredited pharmacists actively providing HMRs and RMMRs**

Category	Number	Percentage of Active accredited pharmacists
Average No. of active accredited pharmacists providing HMR/RMMR services	1074*	50.2%
<b>Total No. of accredited pharmacists (as of 31 October 2022)</b>	<b>2,141</b>	

\*Information sourced from data published by [7CPA Pharmacy Programs Data](#) (last updated 19 October 2022).

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

## Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

The 7CPA provides funding for professional pharmacy programs and services over the life of the Agreement. These programs include continuation and revision of existing pharmacy programs and services from the 6CPA and include:

- **Medication Adherence Programs:** Dose Administration Aids (DAA) and Staged Supply
- **Medication Management Programs:** MedsCheck, Diabetes MedsCheck, Home Medicines Review (HMR), Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) in Residential Aged Care Facilities
- **Aboriginal and Torres Strait Islander Programs:** Indigenous Dose Administration Aids (IDAA) Program and Indigenous Health Services Pharmacy Support (IHSPS) Program

**Table 4-1: Total number and expenditure for Community Pharmacy Programs and Services**

Program or Service	1 January – 30 June 2021		1 July – 31 December 2021		1 Jan- 30 June 2022	
	Total Services	Expenditure	Total Services	Expenditure	Total Services	Expenditure
Dose Administration Aids	8,051,800	\$49,805,646.49	7,932,725	\$49,136,220.04	7,913,876	\$49,031,496.86
Indigenous Dose Administration Aids*	n/a	n/a	635,108	\$7,516,556.40	842,841	\$9,950,897.60
Staged Supply	93,227	\$4,436,152.44	95,958	\$4,598,978.72	92,816	\$4,452,731.48
HMR**	58,429	\$11,409,223.45	60,483	\$11,597,387.77	73,026	\$11,167,055.07
RMMR**	66,364	\$6,621,142.98	77,574	\$7,798,830.17	85,942	\$6,759,047.87
MedsCheck	205,517	\$13,673,064.41	203,819	\$13,560,078.07	185,371	\$12,332,732.63
Diabetes MedsCheck	68,581	\$6,843,812.53	73,837	\$7,368,194.23	74,693	\$7,453,614.47
Quality Use of Medicines in Residential Aged Care Facilities	2865 <sup>a</sup>	\$5,542,684.52	2864 <sup>a</sup>	\$5,942,352.86	2664 <sup>a</sup>	\$5,562,931.48

\* The Indigenous Dose Administration Aids program commenced on 1 July 2021

\*\* Total services for HMR and RMMR programs are inclusive of services paid for first and second follow up,

a – this item reports the average number of participating service providers for this service in any one month during the reporting period. Please note that it does not represent the number of services provided.

Information sourced from [Community Pharmacy Programs data](#) published by the Department of Health and Aged Care.

Objective 4: Ensure all Australians have access to pharmacy services and programs that support the safe and quality use of medicines

### Indigenous Health Services Pharmacy Support (IHSPS) Program

The IHSPS Program was created by merging the Quality Use of Medicines Maximised for Aboriginal & Torres Strait Islander People (QUMAX) and S100 Pharmacy Support Allowance programs, which continued from the 6CPA during the first year of the 7CPA (until 30 June 2021).

The IHSPS Program commenced in July 2021. Table 4-2 below shows the reduction in expenditure during the changeover from QUMAX and S100 Pharmacy Support Allowance programs to the IHSPS program.

**Table 4-2: Number of participating service providers and expenditure recorded for IHSPS Program, QUMAX and S100 Pharmacy Support Allowance**

Program	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure	Average No. of active providers	Expenditure
QUMAX*	84	\$1,303,157.04	N/A	\$60,414.74	N/A	N/A
S100 Pharmacy Support Allowance*	25	\$501,375.00	N/A	\$399,000.00	N/A	N/A
IHSPS Program	N/A	N/A	225	\$1,958,320.75	225	\$1,086,942.26

\* Both QUMAX and S100 Pharmacy Support Allowance programs ceased as stand-alone programs on 30 June 2021.

Information sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) published by the Department of Health and Aged Care.

*Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.*

## Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas

Rural Support Programs are targeted programs and services to support access to PBS medicines and pharmacy services for people living in regional, rural and remote regions of Australia. Services supported under the 7CPA include:

- Regional Pharmacy Maintenance Allowance
- Rural Continuing Professional Education Allowance
- Emergency Locum Service
- Intern Incentive Allowance for Rural Pharmacists
- Incentive Allowance for Rural Pharmacies- Extension Program
- Rural Intern Training Allowance
- Rural Pharmacy Scholarship Scheme
- Rural Pharmacy Scholarship Mentor Scheme
- Rural Pharmacy Liaison Officer Program
- Rural Pharmacy Student Placement Allowance Program and Administrative Support to Pharmacy Schools Scheme

Table 5 (below) provides information on the number of participants and the total expenditure for each of the above programs.

Note that service providers differ based on specific programs and include pharmacists, pharmacy educators, universities and pharmacy interns, in addition to rural and remote hospital and community pharmacies.

Objective 5: Support access to medicines and pharmacy services for people in regional, rural and remote areas.

**Table 5: Number of participating service providers and expenditure recorded for regional, rural and remote pharmacy services**

Program	1 January – 30 June 2021		1 July – 31 December 2021		1 January – 30 June 2022	
	Item	Expenditure	Item	Expenditure	Item	Expenditure
<b>Regional Pharmacy Maintenance Allowance (RPMA)*</b>	1006 <sup>a</sup>	\$9,347,082.50	1049 <sup>a</sup>	\$9,831,037.99	1061 <sup>a</sup>	\$9,893,154.40
<b>Rural Continuing Professional Education Allowance (CPE)</b>	90 <sup>b</sup>	\$65,468.12	48 <sup>b</sup>	\$42,715.34	68 <sup>b</sup>	\$67,536.38
<b>Emergency Locum Service (ELS)</b>	183 <sup>c</sup>	\$229,393.42	36 <sup>§c</sup>	\$39,070.81	63 <sup>c</sup>	\$69,756.39
<b>Intern Incentive Allowance for Rural Pharmacies (IIARP)</b>	38 <sup>d</sup>	\$186,666.67	36 <sup>d</sup>	\$111,666.67	52 <sup>d</sup>	\$269,166.67
<b>Intern Incentive Allowance for Rural Pharmacies - Extension Program (IIRP-EP)</b>	5 <sup>d</sup>	\$55,000.00	5 <sup>d</sup>	\$45,000.00	9.5 <sup>d</sup>	\$70,000.00
<b>Rural Intern Incentive Allowance (RITA)</b>	16 <sup>b</sup>	\$8,890.94	34 <sup>b</sup>	\$19,389.61	21 <sup>b</sup>	\$11,572.97
<b>Rural Pharmacy Scholarship Scheme (RPSS)</b>	71 <sup>d</sup>	\$372,000.00	66 <sup>d</sup>	\$324,500.00	64 <sup>d</sup>	\$284,000.00
<b>Rural Mentor Scheme (RMS)</b>	83 <sup>d</sup>	\$4,875.00	73 <sup>d</sup>	\$21,750.00	74 <sup>d</sup>	\$4,125.00
<b>Rural Pharmacy Liaison Officer (RPLO)</b>	9 <sup>d</sup>	\$234,000.00	9 <sup>d</sup>	\$403,500.00	9 <sup>d</sup>	\$193,500.00
<b>Rural Pharmacy Student Placement Allowance (RPSPA)</b>	16 <sup>e</sup>	\$246,360.37	16 <sup>e</sup>	\$278,587.99	16 <sup>e</sup>	\$219,131.80
<b>Administrative Support to Pharmacy Schools Scheme (ASPSS)</b>	16 <sup>e</sup>	\$146,875.00	16 <sup>e</sup>	\$205,625.00	16 <sup>e</sup>	\$95,468.75

The items reported are; a-Average number of active service providers for RPMA, b- No. of approved claims, c- No. of locum placements, d- Average no. of active participants, e-Average no. of participating universities. This information was sourced from [Rural support and Aboriginal and Torres Strait islander pharmacy programs data](#) published by the Department of Health and Aged Care.

\*From 1 January 2021, RPMA eligibility transitioned from use of the Pharmacy Accessibility/Remoteness Index of Australia (PhARIA) to the [Modified Monash Model \(MMM\)](#) rural classification system.

§ Anecdotal evidence suggests that the number of emergency locum placements were low due to COVID-19 restrictions and lockdowns in place during this period.